Treace Medical Concepts (NASDAQ:TMCI) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Posted by Francis Steltz on Aug 7th, 2026

Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.06, FiscalAI reports. The company had revenue of $45.38 million for the quarter, compared to analyst estimates of $44.02 million. Treace Medical Concepts had a negative return on equity of 67.04% and a negative net margin of 29.44%.

Here are the key takeaways from Treace Medical Concepts’ conference call:

Case volume growth accelerated to high single digits year over year in Q2, supported by market-share gains and broader adoption of Treace’s new bunion systems. Approximately 40% of Lapiplasty surgeons have now used at least one of the three systems launched in 2025.
Treace raised its 2026 revenue guidance to $204 million-$212 million, up from a prior range of $202 million-$212 million, and expects revenue to return to positive growth in the seasonally strong fourth quarter.
Profitability and cash trends improved, with Q2 adjusted EBITDA loss narrowing slightly to $3.5 million, operating expenses falling 8%, and year-to-date cash usage declining 57%. Full-year adjusted EBITDA guidance was improved to a loss of $3 million-$5 million.
The company is expanding beyond bunion procedures through SuperBite, HyperPlate XM, GreatReleaseXM, and planned CartiBlaster launches, which management estimates could expand its U.S. addressable market by approximately $300 million.
Q2 revenue fell 4% to $45.4 million, pressured by lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products. Management expects the associated average selling price headwind to persist through Q3.

Treace Medical Concepts Trading Up 8.7%

Shares of NASDAQ:TMCI traded up $0.38 during mid-day trading on Friday, reaching $4.76. 880,000 shares of the company were exchanged, compared to its average volume of 767,200. Treace Medical Concepts has a 1 year low of $1.17 and a 1 year high of $7.78. The company has a debt-to-equity ratio of 0.72, a current ratio of 3.58 and a quick ratio of 2.53. The firm’s 50-day simple moving average is $4.15 and its 200 day simple moving average is $2.73. The firm has a market cap of $308.78 million, a price-to-earnings ratio of -4.91 and a beta of 1.37.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Wall Street Zen upgraded Treace Medical Concepts from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings raised Treace Medical Concepts from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, Truist Financial upped their target price on Treace Medical Concepts from $2.00 to $4.00 and gave the company a “hold” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Treace Medical Concepts presently has a consensus rating of “Reduce” and a consensus target price of $4.97.

Check Out Our Latest Stock Analysis on TMCI

Insider Transactions at Treace Medical Concepts

In other Treace Medical Concepts news, CEO John T. Treace purchased 22,887 shares of Treace Medical Concepts stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $4.04 per share, with a total value of $92,463.48. Following the completion of the transaction, the chief executive officer owned 7,376,150 shares of the company’s stock, valued at $29,799,646. This trade represents a 0.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders purchased a total of 371,600 shares of company stock valued at $1,104,801 over the last 90 days. 23.42% of the stock is owned by insiders.

Institutional Investors Weigh In On Treace Medical Concepts

Several large investors have recently added to or reduced their stakes in the business. Graham Capital Management L.P. purchased a new position in shares of Treace Medical Concepts in the 4th quarter valued at about $27,000. Osaic Holdings Inc. grew its position in shares of Treace Medical Concepts by 328.3% during the second quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after buying an additional 3,674 shares in the last quarter. HighTower Advisors LLC purchased a new stake in shares of Treace Medical Concepts during the fourth quarter worth approximately $33,000. Kestra Advisory Services LLC purchased a new stake in shares of Treace Medical Concepts during the fourth quarter worth approximately $48,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Treace Medical Concepts in the fourth quarter valued at approximately $54,000. 84.08% of the stock is owned by hedge funds and other institutional investors.

Treace Medical Concepts Company Profile

(Get Free Report)

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.